Merck's Ebola vaccine tees up FDA date, aiming for first status

The FDA has accepted an application for approval of Merck’s Ebola vaccine V920. Merck will learn whether the FDA will approve V920 by mid-March, giving it a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.